Breast Cancer

For patient with osteopenia and frax score less than 20%, or hip fracture risk less than 3% do we need to do bisphosphonates / denosumab in breast cancer patient on aromatase inhibitor?

CNS

I was reading about DOTATATE PET scans for meningiomas and was impressed by the sensitivity of the test. I was wondering how it has impacted your treatment recommendations for grade 1 or 2 meningiomas that are resected?

NHL

Patient in 60s, good PS, with rapidly enlarging bilateral cervical LAD and mediastinal LAD, suv 25 on recent PET scan, size roughly 5 cm in conglomerate of LN in neck, presenting uric acid of 9, with mild pancytopenia, bm involvement 5% by lymphoma. CD 5 and cd 10 negative, b cell lymphoma, high ki67 on core biopsy from cervical node , 11,14 negative on fish, waiting for excisional biopsy from cervical LN. In this kind of scenario, is it advisable to start empiric treatment with RCHOP while inpatient or wait for full results of biospy to make sure it is not double hit or some other aggressive b cell lymphoma?

CRC | Age 35 | New Dx

35 yo female with a locally advanced distal rectal cancer. MSS. CEA 3. Picture of health. Question: Neoadjuvant FOLFIRINOX then chemo (xeloda) + RTx or chemo/RT then chemo (FOLFIRINOX or Cape/Ox, etc). I am leaning toward FOLFIRINOX, Colon Surgery wants chemo/RTx then re-eval but this is clearly TNT to me, just how to arrange the chairs.

Heme

56 y/o F with NF1, sarcoma s/p resection, DVT in lower extremity was on xarelto now with clot extension. She is on oxcarbazepine so might be the reason why she “fail AC”. Are other DOAc such as Padraxa less likely to be affected/less interactions with oxcarb (must have for her)?

Breast Cancer | Age 56 | R/R

Would you combine fam-trastuzumab deruxtecan with endocrine therapy? Results of Phase IB DESTINY-Breast08 trial was promising. I have a 56 yo with metastatic HR+, HER2 low breast cancer who progressed on first line endocrine therapy with anastrozole and Verzenio.